Company intelligence / Profile preview
Burst Biologics
Boise, Idaho, United Statesburstbiologics.com ↗
- Ownership
- Private
- Employees
- ~16
- Development stage
- Other
01
Overview
The company has faced FDA regulatory issues. In 2022, the FDA issued a warning letter stating that their products (BioBurst Fluid and BioBurst Rejuv) were unapproved drugs and biological products, contrary to the company's claim that they were 361 registered tissues.
- Therapeutic areas
- Rheumatology
- Modalities
- Biologics derived from human umbilical cord blood
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Burst Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Burst Biologics.